Erratum: Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial (The Lancet (2018) 391(10125) (1076–1084) (S014067361830206X)(10.1016/S0140-6736(18)30206-X));Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

The Lancet

Volumn 391, Issue 10125, 2018, Pages 1076-1084

  Papi, Alberto ^a   Vestbo, Jørgen ^b   Fabbri, Leonardo ^a,c   Corradi, Massimo ^d   Prunier, Hélène ^e   Cohuet, Géraldine ^e   Guasconi, Alessandro ^e   Montagna, Isabella ^e   Vezzoli, Stefano ^e   Petruzzelli, Stefano ^e   Scuri, Mario ^e   Roche, Nicolas ^f   Singh, Dave ^b,g  

^a UNIVERSITY OF FERRARA   (Italy)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF PARMA   (Italy)

^e CHIESI FARMACEUTICI S P A   (Italy)

^f Institut Cochin   (France)

^g Medicines Evaluation Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; GLUCOCORTICOID; GLYCOPYRRONIUM; INDACATEROL; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATRIAL FIBRILLATION; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; DYSURIA; FEMALE; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HYPERTENSION; LUNG TUMOR; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; THRUSH; XEROSTOMIA; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BECLOMETHASONE; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; GLYCOPYRROLATE; HUMANS; INDANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 85041516663     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30504-X     Document Type: Erratum

References (25)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://goldcopd.org/gold-reports/ (accessed Dec 12, 2017).
2. Worth, H, Buhl, R, Criée, C-P, Kardos, P, Lossi, NS, Vogelmeier, CF, GOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational study. Respir Med 131 (2017), 77–84.
3. Vestbo, J, Vogelmeier, C, Small, M, Higgins, V, Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med 108 (2014), 729–736.
4. Singh, D, Papi, A, Corradi, M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388 (2016), 963–973.
5. Vestbo, J, Papi, A, Corradi, M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 389 (2017), 1919–1929.
6. Wedzicha, JA, Banerji, D, Chapman, KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 374 (2016), 2222–2234.
7. Wedzicha, JA, Decramer, M, Ficker, JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 1 (2013), 199–209.
8. Jones, PW, Beeh, KM, Chapman, KR, Decramer, M, Mahler, DA, Wedzicha, JA, Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 189 (2014), 250–255.
9. Leidy, NK, Murray, LT, Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD 10 (2013), 393–398.
10. Leidy, NK, Murray, LT, Monz, BU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res, 15, 2014, 124.
11. EMA. Draft qualification opinion of qualification of Exacerbations of Chronic Pulmonary Disease Tool (EXACT), and EXACT-Respiratory Symptoms measure (E-RS) for evaluating treatment outcomes in clinical trials in COPD. EMA/CHMP/SAWP/178465/2015. 2015, European Medicines Agency, London.
12. EMA. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). EMA/CHMP/483572/2012. 2012, European Medicines Agency, London.
13. Roche, N, Chapman, KR, Vogelmeier, CF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial. Am J Respir Crit Care Med 195 (2017), 1189–1197.
14. Pascoe, S, Locantore, N, Dransfield, MT, Barnes, NC, Pavord, ID, Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3 (2015), 435–442.
15. Rabe, KF, Beghé, B, Fabbri, LM, Peripheral eosinophil count as a biomarker for the management of COPD: not there yet. Eur Respir J, 50, 2017, 1702165.
16. Cazzola, M, Rogliani, P, Matera, MG, Escalation and de-escalation of therapy in COPD: myths, realities and perspectives. Drugs 75 (2015), 1575–1585.
17. Hurst, JR, Vestbo, J, Anzueto, A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 (2010), 1128–1138.
18. Han, MK, Quibrera, PM, Carretta, EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med 5 (2017), 619–626.
19. Kardos, P, Vogelmeier, C, Worth, H, et al. A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: the DACCORD observational study. Respir Med 124 (2017), 57–64.
20. Melani, AS, Bonavia, M, Cilenti, V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 105 (2011), 930–938.
21. Suissa, S, Dell'Aniello, S, Ernst, P, Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J, 49, 2017, 1602245.
22. Wang, M-T, Liou, J-T, Lin, CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: A nested case-control study. JAMA Intern Med, 2018 published online Jan 2. DOI:10.1001/jamainternmed.2017.7720.
23. Gershon, A, Croxford, R, Calzavara, A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 173 (2013), 1175–1185.
24. Crim, C, Calverley, PMA, Anderson, JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34 (2009), 641–647.
25. Pascoe, SJ, Lipson, DA, Locantore, N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J 48 (2016), 320–330.